Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Lineage Cell Therapeutics Inc (LCTX)

Lineage Cell Therapeutics Inc (LCTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 239,666
  • Shares Outstanding, K 169,976
  • Annual Sales, $ 4,340 K
  • Annual Income, $ -43,020 K
  • 60-Month Beta 1.66
  • Price/Sales 58.73
  • Price/Cash Flow N/A
  • Price/Book 3.28
Trade LCTX with:

Options Overview Details

View History
  • Implied Volatility 526.17% ( +191.47%)
  • Historical Volatility 66.86%
  • IV Percentile 98%
  • IV Rank 43.41%
  • IV High 1,178.79% on 09/16/22
  • IV Low 25.61% on 03/16/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 44
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 4,146
  • Open Int (30-Day) 3,760

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.03
  • Number of Estimates 4
  • High Estimate -0.03
  • Low Estimate -0.04
  • Prior Year -0.05
  • Growth Rate Est. (year over year) +40.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2200 +14.75%
on 11/09/22
1.5100 -7.28%
on 11/23/22
+0.0900 (+6.87%)
since 11/04/22
3-Month
1.0200 +37.25%
on 10/19/22
1.5100 -7.28%
on 11/23/22
+0.1000 (+7.69%)
since 09/06/22
52-Week
1.0200 +37.25%
on 10/19/22
2.7100 -48.34%
on 12/27/21
-0.7200 (-33.96%)
since 12/06/21

Most Recent Stories

More News
Lineage to Present at BTIG Ophthalmology Day and the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley,...

LCTX : 1.3915 (-1.31%)
Lineage Announces Launch of Phase 2a Study by Genentech of RG6501 (OpRegen®) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that its partner Genentech...

LCTX : 1.3915 (-1.31%)
What Makes Lineage Cell (LCTX) a New Buy Stock

Lineage Cell (LCTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

LCTX : 1.3915 (-1.31%)
Lineage Cell (LCTX) Reports Q3 Loss, Misses Revenue Estimates

Lineage Cell (LCTX) delivered earnings and revenue surprises of -33.33% and 26.97%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

LCTX : 1.3915 (-1.31%)
CELU : 1.6050 (-5.03%)
Lineage Cell Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating...

LCTX : 1.3915 (-1.31%)
Berkeley Lights, Inc. (BLI) Reports Q3 Loss, Misses Revenue Estimates

Berkeley Lights, Inc. (BLI) delivered earnings and revenue surprises of -18.52% and 1.22%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

BLI : 2.61 (-5.78%)
LCTX : 1.3915 (-1.31%)
Lineage Cell Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10, 2022

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report...

LCTX : 1.3915 (-1.31%)
Lineage Cell Therapeutics Appoints Jill Howe as Chief Financial Officer

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that Jill Howe will...

LCTX : 1.3915 (-1.31%)
GOSS : 2.28 (-75.46%)
Lineage Announces Notice of Allowance of Two Patents Covering Processes for Manufacturing Allogeneic Oligodendrocyte Progenitor and Retinal Pigmented Epithelium Cells

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that the United States...

LCTX : 1.3915 (-1.31%)
Lineage to Present at Alliance for Regenerative Medicine 2022 Cell & Gene Meeting on the Mesa

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that Brian M. Culley,...

LCTX : 1.3915 (-1.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Lineage Cell Therapeutics Inc. is a clinical-stage biotechnology company. It focuses on developing and commercializing therapies for the treatment of degenerative diseases primarily in the United States and internationally. The company's lead product candidates include OpRegen, OPC1 and VAC2 which are...

See More

Key Turning Points

3rd Resistance Point 1.5600
2nd Resistance Point 1.5300
1st Resistance Point 1.4700
Last Price 1.3915
1st Support Level 1.3800
2nd Support Level 1.3500
3rd Support Level 1.2900

See More

52-Week High 2.7100
Fibonacci 61.8% 2.0644
Fibonacci 50% 1.8650
Fibonacci 38.2% 1.6656
Last Price 1.3915
52-Week Low 1.0200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar